GW CEO: Cannabinoid Platform Is Growth Engine Beyond Epidiolex

 
• By Sten Stovall

Aside from epilepsy in children, GW Pharma also looking to other therapeutic spaces for testing its cannabinoid product candidates, including autism and brain cancer.

Smiling kid child holding a hemp leaf. Concepts of using marihuna for medicinal purposes for children, Medical use of non-psychoactive cannabidiol CBD
GW Hopes Its cannabidiol-based drugs will treat numerous forms of childhood epilepsy • Source: Shutterstock

More from Strategy

More from Business